Bull of the Day: Teradyne (TER)

EPS is expected to rise 29% in FY26 and 16% in FY27, while sales are forecast to grow ~50% in FY26 and ~30% in FY27. Teradyne shares are up over 65% YTD; Q4 sales were $1.1B (+44% YoY, +41% sequentially) and the company has beaten EPS estimates by an average of 18% over the last four releases. Forward valuation sits at ~50.8x next-12-month EPS (near a five-year high), which could amplify volatility if AI infrastructure demand softens.

Analysis

ATE manufacturers, probe-card and handler suppliers, and specialized test-software vendors are the direct beneficiaries of rising per-chip test complexity; higher test time per part translates into effectively higher revenue per tool even without proportionate unit growth, compressing payback periods for vendors with high utilization. Expect upstream suppliers (precision motion, optics, high-frequency interposers) and consumables to see order cadence lead the ATE cycle by 3–6 months — a useful early-warning indicator for order momentum.

The most material tail risks are demand concentration and order lumpiness: a handful of hyperscalers/AI chip designers control a large share of incremental wafer/test demand, so any shift to in-house testing strategies, customer inventory digestion or pause in next-generation tapeouts will produce outsized volatility in bookings. Regulatory or export-control frictions could re-route demand geography, producing near-term dislocations in supplier fill-rates and margin mix as lower-margin regional business substitutes for higher-margin complex-test work.

From a timing lens, earnings and bookings releases over the next 2–8 weeks are the highest-probability catalysts for directional moves, while capital expenditure plans from foundries/OSATs across the next 6–18 months will govern the multi-quarter revenue profile. Structurally, secular growth from AI accelerators supports a multi-year TAM expansion, but the path is jagged — expect multi-quarter stretches where consensus upgrades overshoot as orders are pulled forward and then normalize.

The consensus oversight is behavioural: market prices now bake in sustained high-margin mix and uninterrupted model-level growth; the more realistic scenario is continued beat-and-raise punctuated by 20–40% pullbacks tied to booking volatility. That creates asymmetric, time-limited opportunities for disciplined option or pair strategies that capture upside while protecting against binary booking shocks.

Key Decisions for Investors

• Long TER (equity): establish a core position sized to conviction with a 12–18 month horizon; use a 12–15% trailing stop and plan to trim 30–50% of the position after a 30–40% rally to lock profits against booking volatility.
• TER call-spread (options): buy a 9–12 month call and sell a higher strike to fund premium (target 2:1 upside-to-premium payoff). This captures continued margin/mix expansion while capping cost; allocate no more than 2–3% of portfolio notional to the structure.
• Pair trade to isolate AI-test beta: go long TER and short SMH (or a broad semi ETF) sized to neutralize beta to the capex cycle, time horizon 3–9 months. This extracts idiosyncratic ATE upside while hedging a general semiconductor sentiment reversal; expect >=1.5x gross exposure on TER leg with a cautious rebalance after each earnings print.
• Event hedge into next earnings/bookings release: buy 4–8 week protective puts (~3–5% OTM) for 0.5–1% of position value to limit downside from a negative surprise; if print is positive, let puts expire and redeploy capital into directional exposure.